Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Patent
1997-06-13
1999-11-16
Draper, Garnette D.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
930141, 424 852, C07K 1452, A61K 3819
Patent
active
059860596
ABSTRACT:
The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R1211, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
REFERENCES:
patent: 5017691 (1991-05-01), Lee et al.
patent: 5506107 (1996-04-01), Cunningham et al.
patent: 5723118 (1998-03-01), Dibald
Muller et al, J Mol. Biol 1995, vol. 247, pp. 360-372.
Mornson et al, JBC 267, 1992, pp. 1195-1163.
Powers et al, Science 256, Jun. 1992, pp. 1673-1677.
Kruse et al, EMBO 12(13) 1993, pp. 5121-5129.
Tony et al E. J Biochem 1994.
Kruse et al EMBO 11(9) 1992, pp. 3239-3244.
Kruse et al, FEB Lett 286(1,2) 1991, pp. 58-60.
Care et al, Biochemistry 1991, 30, pp. 1515-1523.
Ngo et al, The Protein Folding Problems and Tertiary Structure Prediction, 1994 ed Merz, p. 433.
Bowie et al, Science 247, 1990, p. 1306.
Frommel et al J. Mol Eval 1985, p. 233, vol. 21.
George et al, Micromolecular Sequencing & Synthesis: Selected Methods 1988, pp. 127-149.
Hilton, D., et al., Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor, PNAS-USA 93: 497-501 (1996).
Obiri, N., Receptor for Interleukin 13, The Journal of Biological Chemistry--vol. 270, No. 15 (1995), pp. 8797-8804.
Matthews, D., et al., Function of the interleukin-2(IL-2) receptor .gamma.-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15, Blood 85(1): 38-42 (1995).
Walter, et al., Crystal structure of a complex between interferon.gamma. and its soluble high-affinity receptor, Nature--vol. 376 (1995), pp. 230-235.
Kondo, M., et al., Sharing of the interleukin-2 (IL-2) receptor .gamma. chain between receptors for IL-2 and IL-4, Science--vol. 262 (1993), pp. 1874-1877.
Russell, S., et al., Interleukin-2 receptor .gamma. Chain: a functional component of the interleukin-4 receptor, Science--vol. 262 (1993), pp. 1880-1883.
Economides, A., et al., Designer cytokines: targeting actions to cells of choice, Science--vol. 270 (1995), pp. 1351-1353.
Wlodawer, A., et al., Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding, Protein Science vol. 2 (1993), pp. 1373-1382.
Kaushansky, K., et al., Hematopoietic growth factors: understanding functional diversity in structural terms, Blood--vol. 82, No. 11 (1993), pp. 3229-3240.
Kruse, N., et al., Two distinct functional sites of human interleukin-4 are identified by variants impaired in either receptor binding of receptor activation, The EMBO Journal--vol. 12, No. 13 (1993), pp. 5121-5129.
Kruse, N., et al., Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement, The EMBO Journal--vol. 11, No. 9 (1992), pp. 3237-3244.
Zurawski, S., Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction, The EMBO Journal--vol. 12, No. 7 (1993) pp. 2663-2670.
Aversa, G., et al., An interleukin-4 (IL-4) mutant protein inhibits both IL-4 or IL-13 induced human immunoglobulin G4 (IgG4) and IgE Synthesis and B cell proliferation: support for a common component shared by IL-4 and Il-13 receptors, J. Exp. Med. 178: 2213-2218 (1993).
Maher, D.W., et al., Human interleukin-4: an immunomodulator with potential therapeutic applications, Progress in Growth Factor Research--vol. 3 (1991), pp. 43-56.
Liblau, R., et al., Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases, Immunology Today--vol. 16, No. 1 (1995), pp. 34-38.
Margolin, K.,et al., Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma, Journal of Immunotherapy--vol. 15, pp. 147-153 (1994).
Schnyder, B., et al., Interleukin-4 (Il-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common .gamma. chain, Blood--vol. 87, No. 10 (1996), pp. 4286-4295.
Callard, R., et al., IL-4 and IL-13 receptors: are they one and the same?, Immunology Today--vol. 17, No. 3 (1996), pp. 108-110.
Morrison, B., et al., A Receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis, The Journal of Biological Chemistry--vol. 267, No. 17 (1992), pp. 11957-11963.
Olins, P., et al., Saturation mutagenesis of human interleukin-3, The Journal of Biological Chemistry--vol. 270, No. 40 (1995), pp. 23754-23760.
Lopez, A., et al., A human interleukin-3 analog with increased biological and binding activities, PNAS (USA)--vol. 89 (1992), pp. 11842-11846.
Lewis, C., et al., Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the offrate of an anti-gp 120 antibody, Molecular Immunology--vol. 32, No. 14 (1995), pp. 1065-1072.
Savino, R., et al., Saturation mutagenesis of the human interleukin-6 receptor-binding site: implications for its three-dimensional structure, PNAS (USA)--vol. 90 (1993), pp. 4067-4071.
Savino, R., et al., Rational design of a receptor super-antagonist of human interleukin-6, The EMBO Journal--vol. 13, No. 24 (1994), 5863-5870.
Lakkis, F., et al., Phe496 and Leu497 are essential for receptor binding and cytotoxic action of the murine interleukin-4 receptor targeted fusion toxin DAB.sub.389 -mIL-4, Protein Engineering--vol. 5, No. 3 (1992), pp. 241-248.
Powrie, F., et al., Cytokine regulation of T-cell function: potential for therapeutic intervention, Immunology Today--vol. 14, No. 6 (1993), pp. 270-274.
Racke, M.K., et al., Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease, J Exp. Med. (USA)--vol. 180, No. 5 (1994), pp. 1961-1966--Abstract.
International Search Report PCT/US97/09286.
Greve Jeffrey
Gundel Robert
Shanafelt Armen B.
Bayer Corporation
Draper Garnette D.
Jones Huw R.
LandOfFree
T-cell selective interleukin-4 agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T-cell selective interleukin-4 agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T-cell selective interleukin-4 agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1326294